These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29673076)

  • 21. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation.
    Benazzo A; Cho A; Nechay A; Schwarz S; Frommlet F; Wekerle T; Hoetzenecker K; Jaksch P
    Trials; 2021 Jan; 22(1):6. PubMed ID: 33397442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
    Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
    Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.
    Shuker N; Bouamar R; Hesselink DA; van Gelder T; Caliskan K; Manintveld OC; Balk AH; Constantinescu AA
    Exp Clin Transplant; 2018 Jun; 16(3):326-332. PubMed ID: 28969528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
    Lee JT; Whitson BA; Kelly RF; D'Cunha J; Dunitz JM; Hertz MI; Shumway SJ
    J Surg Res; 2013 Sep; 184(1):599-604. PubMed ID: 23566442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
    Weir MR; Blahut S; Drachenburg C; Young C; Papademitriou J; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Am J Nephrol; 2004; 24(4):379-86. PubMed ID: 15237243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
    Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
    Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study).
    Anthony C; Imran M; Pouliopoulos J; Emmanuel S; Iliff JW; Moffat KJ; Ross J; Graham RM; Kotlyar E; Muthiah K; Keogh AM; Hayward CS; Macdonald P; Jabbour A
    JACC Heart Fail; 2021 Apr; 9(4):301-313. PubMed ID: 33795116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained-Release Tacrolimus Stabilizes Decline of Forced Expiratory Volume in 1 Second Through Decreasing Fluctuation of Its Trough Blood Level.
    Matsuda Y; Eba S; Hoshi F; Oishi H; Sado T; Noda M; Sakurada A; Watanabe T; Niikawa H; Akiba M; Okada Y
    Transplant Proc; 2018 Nov; 50(9):2768-2770. PubMed ID: 30401394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients.
    Calabrese DR; Florez R; Dewey K; Hui C; Torgerson D; Chong T; Faust H; Rajalingam R; Hays SR; Golden JA; Kukreja J; Singer JP; Greenland JR
    Clin Transplant; 2018 Aug; 32(8):e13332. PubMed ID: 29920787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcineurin Inhibitor-Based Maintenance Immunosuppression in Lung Transplant Recipients: Optimal Serum Levels for Managing Acute Rejection and Renal Function.
    McPheeters CM; Lorenz D; Burcham PK; Barger CD; Bhandari B; Bauldoff GS; Truelove DB; Nunley DR
    Transplant Proc; 2021; 53(6):1998-2003. PubMed ID: 34253383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
    Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of De Novo Mycobacterial Infection After Lung Transplantation Without Rifampicin: Case Series of a Single Institution.
    Suzuki H; Matsuda Y; Noda M; Oishi H; Watanabe T; Sado T; Yamada M; Tamada T; Okada Y
    Transplant Proc; 2018 Nov; 50(9):2764-2767. PubMed ID: 30401393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
    BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular ATP production in CD4+ T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy.
    Schulz-Juergensen S; Burdelski MM; Oellerich M; Brandhorst G
    Ther Drug Monit; 2012 Feb; 34(1):4-10. PubMed ID: 22210096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.